Enhancing Diagnosis, Prognosis, and Therapeutic Outcome Prediction of Gliomas Using Genomics

Overview

Journal OMICS

Specialties Biology
Molecular Biology

Date 2012 Mar 10

PMID 22401657

Citations 18

Authors

Mahfoud Assem

Zita Sibenaller

Supreet Agarwal

Maha S Al-Keilani

Mohammad A Y Alqudah

Timothy C Ryken

Affiliations

Soon will be listed here.

Abstract

Malignant gliomas are the most frequent type of primary brain tumors. Patients' outcome has not improved despite new therapeutics, thus underscoring the need for a better understanding of their genetics and a fresh approach to treatment. The lack of reproducibility in the classification of many gliomas presents an opportunity where genomics may be paramount for accurate diagnosis and therefore best for therapeutic decisions. The aim of this work is to identify large and focal copy number abnormalities (CNA) and loss of heterozygosity (LOH) events in a malignant glioma population. We hypothesized that these explorations will allow discovery of genetic markers that may improve diagnosis and predict outcome. DNA from glioma specimens were subjected to CNA and LOH analyses. Our studies revealed more than 4000 CNA and several LOH loci. Losses of chromosomes 1p and/or 19q, 10, 13, 14, and 22 and gains of 7, 19, and 20 were found. Several of these alterations correlated significantly with histology and grade. Further, LOH was detected at numerous chromosomes. Interestingly, several of these loci harbor genes with potential or reported tumor suppressor properties. These novel genetic signatures may lead to critical insights into diagnosis, classification, prognosis, and design of individualized therapies.

Citing Articles

Genomic, epigenomic and transcriptomic landscape of glioblastoma.

Dakal T, Kakde G, Maurya P Metab Brain Dis. 2024; 39(8):1591-1611.

PMID: 39180605 DOI: 10.1007/s11011-024-01414-8.

Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario.

Bianconi A, Palmieri G, Aruta G, Monticelli M, Zeppa P, Tartara F Biomedicines. 2023; 11(6).

PMID: 37371615 PMC: 10295612. DOI: 10.3390/biomedicines11061520.

Single-Cell Molecular Characterization to Partition the Human Glioblastoma Tumor Microenvironment Genetic Background.

Lessi F, Franceschi S, Morelli M, Menicagli M, Pasqualetti F, Santonocito O Cells. 2022; 11(7).

PMID: 35406690 PMC: 8998055. DOI: 10.3390/cells11071127.

Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

McAleenan A, Jones H, Kernohan A, Robinson T, Schmidt L, Dawson S Cochrane Database Syst Rev. 2022; 3:CD013387.

PMID: 35233774 PMC: 8889390. DOI: 10.1002/14651858.CD013387.pub2.

The tumor suppressor PTPRK promotes ZNRF3 internalization and is required for Wnt inhibition in the Spemann organizer.

Chang L, Kim M, Glinka A, Reinhard C, Niehrs C Elife. 2020; 9.

PMID: 31934854 PMC: 6996932. DOI: 10.7554/eLife.51248.

References

Perry A . Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol. 2001; 8(4):183-99. DOI: 10.1097/00125480-200107000-00001. View

Giannini C, Burger P, Berkey B, Cairncross J, Jenkins R, Mehta M . Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008; 18(3):360-9. PMC: 8095535. DOI: 10.1111/j.1750-3639.2008.00129.x. View

Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R . Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A. 2009; 106(8):2712-6. PMC: 2650331. DOI: 10.1073/pnas.0813314106. View

Engelhard H, Stelea A, Cochran E . Oligodendroglioma: pathology and molecular biology. Surg Neurol. 2002; 58(2):111-7; discussion 117. DOI: 10.1016/s0090-3019(02)00751-6. View

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346(9):645-52. DOI: 10.1056/NEJMoa011573. View

McDonald J, See S, Tremont I, Colman H, Gilbert M, Groves M . The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005; 104(7):1468-77. DOI: 10.1002/cncr.21338. View

Lo K, Rossi M, LaDuca J, Hicks D, Turpaz Y, Hawthorn L . Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer. 2007; 46(10):875-94. DOI: 10.1002/gcc.20474. View

Gupta M, Djalilvand A, Brat D . Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol. 2005; 124(5):755-68. DOI: 10.1309/6JNX-4PA6-0TQ5-U5VG. View

Pegram M, Lipton A, Hayes D, Weber B, Baselga J, Tripathy D . Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16(8):2659-71. DOI: 10.1200/JCO.1998.16.8.2659. View

10.

Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K . Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 2003; 63(4):737-41. View

11.

Acharya C, Hsu D, Anders C, Anguiano A, Salter K, Walters K . Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008; 299(13):1574-87. DOI: 10.1001/jama.299.13.1574. View

12.

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

13.

Huang T, Sarkaria S, Cloughesy T, Mischel P . Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics. 2009; 6(3):500-12. PMC: 3600166. DOI: 10.1016/j.nurt.2009.04.008. View

14.

Sarkaria J, Yang L, Grogan P, Kitange G, Carlson B, Schroeder M . Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007; 6(3):1167-74. DOI: 10.1158/1535-7163.MCT-06-0691. View

15.

Kleihues P, Lubbe J, Watanabe K, von Ammon K, Ohgaki H . Genetic alterations associated with glioma progression. Verh Dtsch Ges Pathol. 1994; 78:43-7. View

16.

Cowell J, Lo K, Luce J, Hawthorn L . Interpreting aCGH-defined karyotypic changes in gliomas using copy number status, loss of heterozygosity and allelic ratios. Exp Mol Pathol. 2009; 88(1):82-9. PMC: 2815113. DOI: 10.1016/j.yexmp.2009.09.014. View

17.

Sathornsumetee S, Reardon D . Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs. 2009; 18(3):277-92. DOI: 10.1517/13543780802692603. View

18.

Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway L . Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006; 2(5):e41. PMC: 1458964. DOI: 10.1371/journal.pcbi.0020041. View

19.

Ostman A, Hellberg C, Bohmer F . Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006; 6(4):307-20. DOI: 10.1038/nrc1837. View

20.

Rich J, Hans C, Jones B, Iversen E, McLendon R, Rasheed B . Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005; 65(10):4051-8. DOI: 10.1158/0008-5472.CAN-04-3936. View